RxDoctor Payments Data

Chandan Kundavaram, MD

Urology · Litchfield Park, AZNPI 1629242714

Payments from drug & device makers

$11,101in general payments, 2019–2025

Across 280 payments — averaging $39.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urogen Pharma, Inc.$3K
  • Boston Scientific$861
  • Caldera Medical, Inc$844
  • Teleflex LLC$786
  • Dendreon Pharmaceuticals LLC$539
  • Coloplast$493
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$8007%
  • Speaking & faculty fees$1,78516%
  • Travel & lodging$4814%
  • Food & beverage$7,88371%
  • Education$1121%
  • Gifts$240%
  • Entertainment$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,101 in reported general payments places this provider in the 75th percentile of 269 urology providers in Arizona.

See all urology providers in Arizona

Medicare billing

Part B allowed, 2024
$880,779
Medicare patients
1,226
Services billed
33,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$183,520
MyrbetriqMirabegron17$12,120
GemtesaVibegron11$9,755
Tamsulosin Hcl410$5,684
Solifenacin Succinate128$4,668
Ciprofloxacin Hcl1,035$2,830
Estradiol40$1,701
Trospium Chloride46$1,402
Testosterone Cypionate21$1,035
Oxybutynin Chloride ErOxybutynin Chloride54$877
Bicalutamide33$746
Finasteride46$696
Alfuzosin Hcl ErAlfuzosin Hcl22$451
Betamethasone Dipropionate12$329
Cephalexin50$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$62$195,64130 claims
Sumitomo Pharma America, Inc.Gemtesa$170$9,75511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 269 urology providers in Arizona.

Other urology in Litchfield Park

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →